Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiac Catheterization II: Right Heart Catheterization01:21

Cardiac Catheterization II: Right Heart Catheterization

Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraventricular spring expander attenuates cardiac atrophy of the failing heart after unloading caused by heterotopic heart transplantation: no sex-linked differences.

Physiological research·2025
Same author

Sex-Linked Differences in Cardiac Atrophy After Heterotopic Heart Transplantation: No Direct Relation to the Actions of Sex Steroid Hormones.

Physiological research·2024
Same author

Influence of implant strategy on the transition from temporary left ventricular assist device to durable mechanical circulatory support.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2024
Same author

Sex-Linked Differences in Cardiac Atrophy After Mechanical Unloading Induced by Heterotopic Heart Transplantation.

Physiological research·2024
Same author

Cell Differentiation and Aging Lead To Up-Regulation of FTO, While the ALKBH5 Protein Level Was Stable During Aging but Up-Regulated During in vitro-Induced Cardiomyogenesis.

Physiological research·2023
Same author

Plant extracellular vesicles and their potential in human health research, the practical approach.

Physiological research·2022
Same journal

Pharmacological profile of mepolizumab.

Vnitrni lekarstvi·2023
Same journal

Atypical form of Goodpasture's disease.

Vnitrni lekarstvi·2023
Same journal

Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations.

Vnitrni lekarstvi·2023
Same journal

Dyslipidemia - the known unknown.

Vnitrni lekarstvi·2023
Same journal

Internal comorbidities and complications of multiple sclerosis therapy - don't be caught off guard!

Vnitrni lekarstvi·2023
Same journal

Implications of highly suppressive treatment HIV infection.

Vnitrni lekarstvi·2023
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

[Right ventricular dysfunction after left ventricular assist device implantation].

H Ríha1, I Netuka, T Kotulák

  • 1Klinika anesteziologie a resuscitace, Kardiocentrum IKEM Praha. hynek.riha@ikem.cz

Vnitrni Lekarstvi
|February 27, 2010
PubMed
Summary
This summary is machine-generated.

Aggressive management of right ventricular dysfunction after left ventricular assist device (LVAD) implantation is crucial. This includes extensive pharmacological support and, in some cases, mechanical support with a right ventricular assist device (RVAD) to improve outcomes.

More Related Videos

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Related Experiment Videos

Last Updated: Jun 15, 2026

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Medical Devices

Context:

  • Left ventricular assist device (LVAD) implantation is increasingly common for advanced heart failure.
  • Right ventricular dysfunction or failure post-LVAD significantly impacts patient morbidity and mortality.
  • Effective management strategies for RV dysfunction after LVAD are critical.

Purpose:

  • To assess the management of right ventricular dysfunction following HeartMate II LVAD implantation.
  • To evaluate the use of pharmacological and mechanical support for the right ventricle.
  • To analyze clinical outcomes in patients with RV dysfunction post-LVAD.

Summary:

  • A retrospective study of 21 HeartMate II LVAD patients (2006-2009) evaluated RV support strategies.
  • Pharmacological support included dobutamine, milrinone, isoproterenol, and levosimendan; inhaled nitric oxide was also used.
  • Despite extensive support, 14.3% required right ventricular assist device (RVAD) implantation; survival to transplantation was 42.8%.

Impact:

  • Aggressive pharmacological and mechanical support for right ventricular function is necessary after LVAD implantation.
  • Optimizing RV function post-LVAD is essential to minimize patient morbidity and mortality.
  • This study highlights the need for tailored RV support strategies in LVAD recipients.